Pharma BD Deal Intelligence
Diversifies Vertex beyond CF into oral endocrinology with a launched drug + Phase 3 asset
Full analysis, sources & comparables →Vertex's $10B foray into endocrine disease with acromegaly drug Palsonify and CAH candidate atumelnant.
Vertex to acquire Crinetics for $85.00/share in cash, ~$10.0B equity value; adds PALSONIFY and atumelnant.
Vertex's largest acquisition to date; ~$5B combined peak sales; expected close Q3 2026; $4.5B committed bridge financing.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Vertex Pharmaceuticals Incorporated agreed on July 6, 2026 to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash — an all-cash transaction valued at approximately $10.0 billion in equity (~$8.8 billion net of estimated cash acquired), Vertex's largest acquisition to date. The deal adds PALSONIFY (paltusotine), the first once-daily oral nonpeptide somatostatin receptor type 2 (SST2) agonist, FDA-approved in September 2025 for acromegaly, and atumelnant, a once-daily oral ACTH (MC2R) receptor antagonist in pivotal Phase 3 (CALM-CAH) for classic congenital adrenal hyperplasia and Phase 1/2b for ACTH-dependent Cushing's syndrome. Vertex cites a combined ~$5 billion peak-sales opportunity, expects to close in Q3 2026, and is funding the deal with cash on hand plus $4.5 billion of committed bridge financing from Bank of America and Morgan Stanley.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. (this deal) | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2023 | $330M | — |
| Vertex Pharmaceuticals Incorporated / Exonics Therapeutics, Inc. | 2019 | $1.0B | — |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2021 | $1.1B | — |
| Vertex Pharmaceuticals Incorporated / Alios BioPharma, Inc. | 2011 | $1.5B | — |
← Browse all deals · How we score deals
More: 2026 deals · Vertex Pharmaceuticals Incorporated deals · Metabolic deals